Name: LY2584702
Brand: Selleck Chemicals
SKU: S7698
Availability: InStock
Rating: 5 (26 reviews)

Jump to

Quality Control

Batch: Purity: 99.02%

99.02

Related Targets	PI3K Akt mTOR GSK-3 ATM/ATR DNA-PK AMPK PDPK1 PTEN PP2A
Other S6 Kinase Inhibitors	PF-4708671 BI-D1870 LY2584702 Tosylate LJI308 LJH685 3'-Hydroxypterostilbene BRD7389 S6K-18 L-Norvaline Gingerenone A

Solubility

In vitro
Batch:

DMSO : 4.44 mg/mL (9.96 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.500mg/ml (3.37mM)
	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.370mg/ml (0.83mM)

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	445.42	Formula	C₂₁H₁₉F₄N₇	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1082949-67-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CN1C=C(N=C1C2CCN(CC2)C3=NC=NC4=C3C=NN4)C5=CC(=C(C=C5)F)C(F)(F)F

Mechanism of Action

Targets/IC₅₀/Ki	p70S6K 4 nM
In vitro	In HCT116 colon cancer cells, LY2584702 inhibits phosphorylation of the S6 ribosomal protein (pS6) with IC50 of 0.1-0.24 μM. This compound has significant synergistic effects when combined with EGFR inhibitor or with the mTOR inhibitor.
In vivo	LY2584702 (12.5 mg/kg BID), demonstrates significant antitumor efficacy in both U87MG glioblastoma and HCT116 colon carcinoma xenograft models.
References	[1] https://pubmed.ncbi.nlm.nih.gov/24440085/ [2] https://pubmed.ncbi.nlm.nih.gov/24456794/ [3] https://pubmed.ncbi.nlm.nih.gov/35508467/

Applications

Methods	Biomarkers	Images	PMID
Western blot	p-rpS6 / rpS6 / p-RPS6KB1 / RPS6KB1		28792981

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01241461	Completed	Cancer	Eli Lilly and Company	November 2010	Phase 1
NCT01115803	Terminated	Metastases Neoplasm\|Carcinoma Non-small Cell Lung\|Renal Cell Carcinoma\|Neuroendocrine Tumors	Eli Lilly and Company	March 2010	Phase 1
NCT01394003	Terminated	Advanced Cancer	Eli Lilly and Company	November 2008	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
what is the difference between S7698 and S7704? Ie., what does the tosylate group do?

Answer:
It is the free base of the compound and its tosylate salt. Chemically, the salt form is more stable and has a better solubility than the free base, however, it also has a higher molecular weight. Biologically, these two forms have the same activities.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

LY2584702 S6 Kinase inhibitor

Chemical Structure

Molecular Weight: 445.42